Biological Markers of Recovery for the Kidney

肾脏恢复的生物标志物

• 批准号: 7031481
• 负责人: John A Kellum
• 金额: $ 36.74万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-01 至 2011-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7031481
• 关键词: acute renal failure; biomarker; blood tests; clinical research; clinical trials; cooperative study; gene expression; hemodialysis; human subject; human therapy evaluation; inflammation; kidney function; mass spectrometry; mathematical model; oxidative stress; prognosis; protein quantitation /detection; surface enhanced laser desorption ionization; urine

DESCRIPTION (provided by applicant): NIDDK, together with the VA Cooperative Studies Program, recently funded a large therapeutic trial in ARF. This trial, known as the ARF Trial Network (ATN) study CSP530, will randomize 1164 patients at 27 centers to normal versus high-dose renal replacement therapy. Under the Program Announcement, PAR-04-078 for ancillary studies to NIDDK-funded clinical trials, we propose to augment the ATN-CSP 530 Study with an evaluation of a set of candidate biological markers of recovery for the kidney (BioMaRK). Preliminary evidence suggests genetic, inflammatory, and clinical factors all play a role and there is mounting interest in the question of whether the way in which renal replacement therapy is provided influences the clinical course. The central goal of BioMaRK is to better understand the role of two key pathways, inflammation and oxidative stress, in survival and recovery of renal function after ARF. We will also look at genetic variation, not only in genes coding for inflammatory mediators, but also other key components of the injury-to-repair continuum. Additionally, we will seek new markers of renal injury and repair by mass spectrometric examination of the urine. Finally, in keeping with the NIH Roadmap, in order to understand the clinical utility of this work, we will build a clinical risk prediction model that will consider plasma mediator levels, urine markers, genetic, and clinical variables. We will use the ATN-CSP 530 trial cohort as an inception cohort of patients with newly established ARF. For most analyses, we propose to study the entire portion of the ATN-CSP530 trial cohort that consents to the blood sample and DNA bank (815 patients). For analyses requiring serial samples and urine samples, we propose to study a subset of trial patients enrolled at 5 sites who consent to additional sample collection (208 patients)

描述（由申请人提供）：NIDDK与VA合作研究计划一起，最近资助了ARF的大型治疗试验。这项试验被称为ARF试验网络（ATN）研究CSP530，将在27个中心随机分配1164名患者进行正常和高剂量肾脏替代治疗。根据项目公告PAR-04-078对niddk资助的临床试验的辅助研究，我们建议通过评估一组候选肾脏恢复生物标志物（BioMaRK）来增加ATN-CSP 530研究。初步证据表明，遗传、炎症和临床因素都发挥了作用，人们对提供肾脏替代治疗的方式是否影响临床病程的问题越来越感兴趣。